Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May 25;1(3):e000013.
doi: 10.1136/esmoopen-2015-000013. eCollection 2016.

Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma

Alejo Rodriguez-Vida  1 , Michiel Strijbos  2 , Thomas Hutson  3
Affiliations
Review

Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma

Alejo Rodriguez-Vida et al. ESMO Open. .

Abstract

In the past decade, several agents targeting angiogenesis and signal transduction pathways have replaced the use of cytokines as standard of care treatment for metastatic renal cell carcinoma (RCC) after showing improved clinical benefit and survival. Currently, several novel immunotherapy agents targeting the programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) pathways are being tested in metastatic RCC and are bound to revolutionise the management of this disease. However, the success of both antiangiogenic drugs and new immunotherapy agents still depends on our ability to select patients most likely to respond to treatment. This article will review the current available evidence on prognostic and predictive biomarkers of response to signal transduction pathways-targeted agents and modern immunotherapy in metastatic RCC.

Keywords: Biomarker; Immunotherapy; Programmed cell death-1; Renal cell carcinoma; Tyrosine kinase inhibitor.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

References

    1. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061–8. 10.1200/JCO.2009.23.9764 - DOI - PubMed
    1. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115–24. 10.1056/NEJMoa065044 - DOI - PubMed
    1. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–81. 10.1056/NEJMoa066838 - DOI - PubMed
    1. Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378:1931–9. 10.1016/S0140-6736(11)61613-9 - DOI - PubMed
    1. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449–56. 10.1016/S0140-6736(08)61039-9 - DOI - PubMed